Navigation Links
Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
Date:5/16/2008

HOUSTON - Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center.

These findings are surprising and represent the first positive study for Iressa in breast cancer, as well as for the entire class of drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, said Massimo Cristofanilli, M.D., the study's principal investigator.

Cristofanilli will present the findings at the American Society for Clinical Oncology's (ASCO) upcoming annual meeting as an oral presentation.

"We initiated this study in 2003 with hopes of reducing the resistance to hormonal therapy," said Cristofanilli. "There was a lot of preclinical work indicating that, in fact, resistance to hormonal therapy is strongly associated with an activated EGFR pathway. Also, EGFR over-expression has been associated with endocrine resistance. If there's a double blockage of the EGFR and the estrogen receptor, you may achieve better control of the disease."

The Phase II study enrolled 93 women from 30 centers across the United States and Latin America, with M. D. Anderson enrolling 20 patients. All of the women were newly diagnosed with metastatic breast cancer and were hormone receptor positive and estrogen receptor HER-2 negative. Patients were randomized to receive the aromatase inhibitor Arimidex (1 milligram) and Iressa (250 milligram) daily or Arimidex and placebo. The primary endpoint was progression-free survival.

When the study was unblinded, the researchers were surprised by the distinct findings: in the women who received Arimidex and Iressa, progression-free survival was 14.5 months, compared to 8.2 months in the women who did not receive Iressa, representing a 45 percent reduction in risk.

Additionally, of the women taking the combination, 47 percent had stable disease for more than 24 weeks and 49 percent had a clinical benefit. In contrast, 22 percent of the women had taking Arimidex alone had stable disease for more than 24 weeks and 34 percent had a clinical benefit.

Patients in the combination arm did have a higher rate of adverse events, but Cristofanilli notes that overall Iressa was very well tolerated.

"To see such a difference in such a small subset of patients was tremendously surprising," said Cristofanilli. "These findings show the possibility of adding a targeted therapy such as Iressa or others in the EGFR drug class to improve the benefit for hormonal therapy, giving another option for women who are hormone receptor positive, Her-2 negative with metastatic disease."

About 60 percent of women with breast cancer are hormone receptor positive and Her-2 negative, said Cristofanilli.

Iressa, a once-daily, oral tablet, was the first in a new class of anti-cancer drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, to become commercially available. Iressa received FDA approval May 5, 2003 as a single agent treatment for patients whose advanced lung cancer has continued to progress despite treatment with platinum-based and docetaxel chemotherapy.

However, in 2005, after a large international study resulted in negative findings and reported numerous negative side effects, the drug's labeling was altered by the FDA. Only cancer patients who had already taken the medicine and whose physician believed it was helping them were allowed to receive the drug. No new lung cancer patients were given the drug after this time.

During this period, Iressa was being tested in clinical trials in a number of cancer types, including breast cancer. Other breast cancer trials studying Iressa, either as a single agent or when combined with chemotherapy, were mostly negative.

These negative findings impacted the accrual of the Arimidex-Iressa breast cancer study, said Cristofanilli. The study fell well short of its accrual goal of 174 women.

"Still, there's significant clinical relevance to our findings. Of course, I would advise that physicians not rush to put metastatic breast cancer patients who are hormone receptor positive and estrogen receptor negative on other drugs in this class that are readily available," said Cristofanilli. "Rather, this study should serve as a proof-of-concept. With our results, there should be a renewed interest in this class of drugs and hopefully follow-up studies in the adjuvant setting will be conducted."


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
2. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
3. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
4. Kids Growing Up on Grown Up Drugs: New Research Shows Treatments for Adult Ailments Rapidly Rising in Children
5. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
6. New Survey Shows Americans Value Oral Health But Knowledge Gap Remains
7. Research shows HPV testing offers women protection for twice as long as smear testing
8. Study shows that prostate cancer increases the risk of bone fracture
9. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
10. Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas
11. Expanded food and nutrition program shows $10 benefit for each $1 spent
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
(Date:4/29/2016)... ... 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out ... earning them second place for Tampa’s Best Places to Work. They were ranked in ... a great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We ...
(Date:4/29/2016)... San Rafael, CA (PRWEB) , ... April 29, 2016 , ... ... a week long softball camp from July 24th – 27th for girls aged 10-18. ... The camp is held at the beautiful Clark V. Whited Complex, one of the ...
(Date:4/29/2016)... ... 29, 2016 , ... HEALTHCAREfirst , the leading provider ... Deyta Analytics, recently announced the recipients of the fourth annual Hospice Honors, a ... from the caregiver’s point of view. The official list of recipients was unveiled ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec ... held May 16th to 18th at the Broward County Convention Center. The event ... to collaborate on best practices in public facility management. Intellitec Solutions will highlight ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and ... highlighting inconsistencies of adding BC and AD, saying it is time to set the ... After Christ. Yisrayl says this simply cannot possibly be true and offers explanation. , ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Elekta today announced ... will be the focal point of seven scientific presentations ... Society for Radiotherapy & Oncology, taking place April 29 ... state-of-the-art radiotherapy system and a high-field MRI scanner with ... the patient,s anatomy in real time. The MR-linac is ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... , April 27, 2016 ... USD 2.14 billion by 2022, according to a ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... affecting the efficiency and accuracy delivered by the ... demand for novel urinalysis instruments and consumables. For ...
Breaking Medicine Technology: